Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jiangsu Hengrui Pharmaceuticals | Hong Kong | Healthcare | Pharmaceuticals | HK$467.32B | 60.4x | 1.78 | HK$81.80 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 20.7% Upside | Upgrade to Pro+ | |
Hansoh Pharmaceutical Group | Hong Kong | Healthcare | Pharmaceuticals | HK$209.83B | 39.9x | 7.08 | HK$35.12 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.2% Upside | Upgrade to Pro+ | |
Innovent Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$146.61B | 115.6x | 0.71 | HK$85.60 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.1% Upside | Upgrade to Pro+ | |
Sino Biopharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$134.61B | 32x | -9.26 | HK$7.51 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27% Upside | Upgrade to Pro+ | |
CSPC Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$104.27B | 25x | -0.78 | HK$9.10 | 3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.5% Upside | Upgrade to Pro+ | |
Shanghai Fosun Pharmaceutical | Hong Kong | Healthcare | Pharmaceuticals | HK$82.41B | 23.5x | 0.29 | HK$23.82 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 25% Upside | Upgrade to Pro+ | |
WuXi XDC Cayman | Hong Kong | Healthcare | Pharmaceuticals | HK$80.06B | 66.9x | 0.57 | HK$69.60 | 6.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 5% Upside | Upgrade to Pro+ | |
Shanghai Pharma Holding | Hong Kong | Healthcare | Pharmaceuticals | HK$74.40B | 11.2x | 0.21 | HK$12.11 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 15.3% Upside | Upgrade to Pro+ | |
3SBio | Hong Kong | Healthcare | Pharmaceuticals | HK$66.07B | 26.4x | 0.64 | HK$27.56 | 4.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 36.2% Upside | Upgrade to Pro+ | |
Sinopharm Group Co | Hong Kong | Healthcare | Pharmaceuticals | HK$57.86B | 7.8x | -0.38 | HK$18.52 | 0.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.4% Upside | Upgrade to Pro+ | |
Guangzhou Baiyunshan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$45.57B | 14.9x | -0.54 | HK$18.19 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.5% Upside | Upgrade to Pro+ | |
Asymchem Laboratories Tianjin | Hong Kong | Healthcare | Pharmaceuticals | HK$41.56B | 35.6x | -35.98 | HK$91.10 | 7.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.2% Upside | Upgrade to Pro+ | |
Shanghai Junshi Biosciences | Hong Kong | Healthcare | Pharmaceuticals | HK$38.26B | -28.7x | -0.79 | HK$26.16 | -0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.3% Upside | Upgrade to Pro+ | |
Henlius Biotech | Hong Kong | Healthcare | Pharmaceuticals | HK$36.20B | 47.8x | 2.23 | HK$70.20 | 5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
China Medical System | Hong Kong | Healthcare | Pharmaceuticals | HK$32.94B | 18.3x | 0.93 | HK$13.68 | 4.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 27.7% Upside | Upgrade to Pro+ | |
Simcere | Hong Kong | Healthcare | Pharmaceuticals | HK$30.84B | 32.2x | 0.18 | HK$12.26 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37% Upside | Upgrade to Pro+ | |
China Resources Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$30.34B | 9.9x | -0.39 | HK$4.84 | 1.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.5% Upside | Upgrade to Pro+ | |
Livzon Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$29.33B | 15.9x | 1.32 | HK$32.94 | 2.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 12.8% Upside | Upgrade to Pro+ | |
China Grand Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$28.92B | 13.9x | -1.02 | HK$8.29 | 4.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.9% Upside | Upgrade to Pro+ | |
Duality Biotherapeutics | Hong Kong | Healthcare | Pharmaceuticals | HK$26.85B | -2.4x | HK$314 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 40.5% Upside | Upgrade to Pro+ | ||
United Laboratories Int | Hong Kong | Healthcare | Pharmaceuticals | HK$26.34B | 7.3x | 1.52 | HK$13.35 | 1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 42.2% Upside | Upgrade to Pro+ | |
Sunshine Lake Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$25.58B | 21x | -0.69 | HK$45.70 | 3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -68.8% Downside | Upgrade to Pro+ | |
Zai Lab | Hong Kong | Healthcare | Pharmaceuticals | HK$25.44B | -17.6x | -0.47 | HK$23.28 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
HUTCHMED | Hong Kong | Healthcare | Pharmaceuticals | HK$20.42B | 5.8x | 0 | HK$24.20 | 2.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.6% Upside | Upgrade to Pro+ | |
Shenzhen Hepalink | Hong Kong | Healthcare | Pharmaceuticals | HK$18.91B | 42.9x | 0.15 | HK$5.40 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -18.9% Downside | Upgrade to Pro+ | |
Cansino Biologics | Hong Kong | Healthcare | Pharmaceuticals | HK$15.05B | -69.9x | -1.06 | HK$45.26 | 2.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.1% Upside | Upgrade to Pro+ | |
Pegbio | Hong Kong | Healthcare | Pharmaceuticals | HK$14.52B | -79.4x | HK$52.25 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Sihuan Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$13.85B | -158.3x | 1.49 | HK$1.53 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.5% Upside | Upgrade to Pro+ | |
Luye Pharma Group | Hong Kong | Healthcare | Pharmaceuticals | HK$13.82B | 29.4x | -0.65 | HK$3.52 | 8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.5% Upside | Upgrade to Pro+ | |
Consun Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$13.41B | 12.3x | 0.91 | HK$15.77 | 5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 14.9% Upside | Upgrade to Pro+ | |
160 Health International | Hong Kong | Healthcare | Pharmaceuticals | HK$12.91B | -246.8x | HK$39.04 | 1.8% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
China Traditional Chinese Medicine | Hong Kong | Healthcare | Pharmaceuticals | HK$12.29B | -42.5x | 0.32 | HK$2.44 | 1.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -33.9% Downside | Upgrade to Pro+ | |
Hbm | Hong Kong | Healthcare | Pharmaceuticals | HK$10.91B | 21.5x | 0.09 | HK$13.31 | 2.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -1.9% Downside | Upgrade to Pro+ | |
CStone | Hong Kong | Healthcare | Pharmaceuticals | HK$9.93B | -22.5x | 0.15 | HK$6.82 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 39.4% Upside | Upgrade to Pro+ | |
Ascletis Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$9.53B | -33x | 5.06 | HK$9.55 | 4.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
SSY Group | Hong Kong | Healthcare | Pharmaceuticals | HK$8.40B | 12.9x | -0.26 | HK$2.88 | 1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 47.4% Upside | Upgrade to Pro+ | |
Shanghai Fudan-Zhangjiang Bio-Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$8.06B | -139.5x | 2.45 | HK$3.33 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beijing Tong Ren Tang | Hong Kong | Healthcare | Pharmaceuticals | HK$7.40B | 14.4x | 3.36 | HK$8.84 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 26.1% Upside | Upgrade to Pro+ | |
Shandong Boan Biotechnology | Hong Kong | Healthcare | Pharmaceuticals | HK$6.98B | 204.4x | -4 | HK$11.78 | 5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -11.7% Downside | Upgrade to Pro+ | |
China Shineway Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$6.46B | 7.2x | -0.28 | HK$8.55 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -0.2% Downside | Upgrade to Pro+ | |
Ocumension | Hong Kong | Healthcare | Pharmaceuticals | HK$6.18B | -24x | -0.76 | HK$7.74 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.7% Upside | Upgrade to Pro+ | |
Tong Ren Tang Tech | Hong Kong | Healthcare | Pharmaceuticals | HK$6.10B | 13x | -0.39 | HK$4.75 | -0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 30.3% Upside | Upgrade to Pro+ | |
VIVA Biotech Holdings | Hong Kong | Healthcare | Pharmaceuticals | HK$5.42B | 45x | 0.19 | HK$2.71 | 5.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 48.9% Upside | Upgrade to Pro+ | |
Shandong Xinhua Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$4.80B | 25.9x | -1.68 | HK$7.26 | 1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
AIM Vaccine | Hong Kong | Healthcare | Pharmaceuticals | HK$4.78B | -17x | -0.22 | HK$4 | 2.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Beijing Luzhu Biotechnology | Hong Kong | Healthcare | Pharmaceuticals | HK$4.76B | -33.7x | -0.66 | HK$24.40 | 2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.8% Upside | Upgrade to Pro+ | |
Jacobson Pharma | Hong Kong | Healthcare | Pharmaceuticals | HK$2.89B | 9.6x | 1.07 | HK$1.45 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Cutia Therapeutics | Hong Kong | Healthcare | Pharmaceuticals | HK$2.83B | -5.4x | -0.47 | HK$8.43 | 4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Golden Throat | Hong Kong | Healthcare | Pharmaceuticals | HK$2.65B | 9x | 3.98 | HK$3.60 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Essex Bio-Tech | Hong Kong | Healthcare | Pharmaceuticals | HK$2.59B | 9.4x | 0.38 | HK$4.77 | 4.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 43.4% Upside | Upgrade to Pro+ |